<DOC>
	<DOCNO>NCT02385981</DOCNO>
	<brief_summary>H-1 : tcpO2U2 &gt; tcpO2U1 H-0 : tcpO2U2 â‰¤ tcpO2U1</brief_summary>
	<brief_title>Vagal-stimulation-PAVK-tcpO2-study</brief_title>
	<detailed_description />
	<criteria>1 . Each subject must sign informed consent ( ICF ) indicate understands purpose procedure require study willing participate study . 2 . PAVK stadium IIb due Fontaine least 6 month 3. reduce systolic occlusion pressure ankle ( arteria tibialis posterior anterior ) : ABI &lt; 0,9 4. radiologic significant occlusion arteria femoralis superficialis and/or arteria poplitea and/or arteria low leg ( MRT , CT , CO2angiography colorcoded duplex sonography ) 5. expect availability study participation 12 week ( via health care center ) 1 ) &lt; 18 year 2 ) pregnancy nonexclusion pregnancy ( woman childbearing potential ) 3 ) risk incidence pregnancy study participation ( female must fulfill one follow criterion : menopause 2 year , postmenopausal sterilisation , surgical sterilisation , hormonal contrazeption study participation , spiral diaphragm/condome+spermicide ) . 4 ) lactation period 5 ) person legal incapacity 6 ) regard , placement appointment solicitor 7 ) military service 8 ) contraindication application STIVAX 8a ) malignant tumour ( existence know , histologic verify , malignant tumour ) 8b ) hemophilia 8c ) psoriasis vulgaris 8d ) recent stroke 8e ) superficial deep infection auricle external auditory canal 9 ) ( exception STIVAXapplication ) : foreseeable relevant stimulation afferent content vagus ear within next 2 week . 10 ) isolate diabetic microangiopathia 11 ) implantated cardiac pacemaker defibrillator 12 ) transcutaneous partial pressure oxygen ( tcpO2 ) &gt; 50 mmHg 13 ) concomitant disease potential limit significance investigation walk distance ( angina pectoris , heart failure , relevant pulmonary disease , relevant orthopedic neurologic disease ) 14 ) concomitant disease potential improve worsen walk perfusion extremity relevant way . 15 ) foreseeable change PAVKrelevant medication concomitant medication potential improve worsen walk perfusion extremity relevant way within next 2 week . 16 ) foreseeable start structure walk train within next 2 week . 17 ) change PAVK relevant medication concomitant medication potential improve worsen walk perfusion extremity relevant way within last 3 month . 18 ) start structure walk training within last 3 month . 19 ) change smoke habit within last 3 month . 20 ) simultaneous participation another clinical trial insuranceprotection . 21 ) use therapy stimulation afferent part vagus ear past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>